Novartis already owns over 12% of the shares of the ALNY, and then on Feb 1st they bought $14 Million worth of shares of ALNY at a cost of $69/ share. ALNY has over $1 Billion in cash. Can someone add 2 and 2 together, if this does not mean Novartis is planning to take over ALNY, I don't know what does.
If all paitients were staying with prescrition, the TRX should be in thousand or more after over a year drug being sold. Obviously paitients are not staying with the drug, Europe is also only $300 Million total market, much smaller than US, so approval there don't mean anything, they are not going to attempt to sell it there themselves, and have had no luck finding a partner. I sold most of my holding, will get back in when TRX starts running into 1000s. I think Klarman made mistake, everyone makes mistake here and there, this drug does not pull it's own weight, it is a failure.
Do shareholders a favor, and do not venture to appear on CNBC. I think shareholders, myself included were on this stock for stability and hopes for dividend growth, now comes the adventurous CEO. The buy however should not be dilutive, the earning were 40% higher at FMER..
You make sense, but I would have like to see Cramer bring it up.
I do not understand what is so smart about this acquisition. The one that made it like a bandit is the hedge fund that flipped this asset for a price of over 4 fold in less than 2 years. Why Cramer did not question his guest about the purchase price? I suppose company is careless about the price because it figures she can raise the price of the drug, but the price have already been increase quite a bit in last 3 years. Our healthcare costs are balloning because of such actions.
For the period that the inventory fell by 58 Billion cubic feet, we had spring like weather. This implies that the supply has started coming down, add to that the fact that LNG has started shipping nt gas from US. the toal shipment by LNG from US expected to be over 2500 bcf per year, imagin what that will do to inventory which stands at under 4000 bcf.
I listened to see what you are talking about. I have been and listened to many of this sort of presentations. Obviously to me you have no experience as to what company presentation is all about. You do not expect the presenter to do song and dance, they present facts which he did, presenter most of the time has a prepared remarks which he did, I did not detect any nervousness at all. What is your problem why do you say mean and untrue things. some presenters when they do many of these will not read from notes as he did. would I rate his performance as 10, no, I would rate it a 7.5. As to having new material, rarely on these presentation there is any new material, these are not a platform to announce new material, but to educate the investors that have not heard about the company. At least educate yourself before making a public judgement.
I made error in my calculations, and you geniusess did not pick it up either. The number is ( 660)X ($925)X ( 1/7) X(90)= $7.8 Million which is still much higher than average estimates and over the high estimate.
If you google the price of Auryxia, the Pharmacies sell the drug at the cheapest for $925 with coupon. At IMS sales of 400 RX/week which is 60% of the sales, the total RX is 660/ week, therefore quarterly sales= ($925)X( 1/7)X (90) = $11,000,000. This is much higher than analyst estimate.
Investment banks love this company, they keep getting business from it. They sold the recent buy to them at $510 Million, which was bought for $120 Million by a hedge fund 2 years ago, to pay for it sooner or later they will sell stocks on secondary offerings, cash register ringing for investment bankers.
This fund used to be managed by Solom Brothers and did very well, Since Legg Mason took over, it has been nothing but down the hill. I am suspicious of managements motive on merging the two funds. I think GDF has 5% exposure to energy, I am not sure about EHI.
I am affraid he price of the crealta drug has already been increaed from $2000 to $14000. Horizon has 2 cl#$%$ of products, repackaged generic over the counter products, and a few clinical stage drugs with no guarantee that they will work. When the payers plug the holes and prevent Horizon from selling their revenue generating drugs, earning will plummet, and the debt will come back and bite the company in the #$%$. I do not agree with what PBM are doing and not including the drugs on their fomularies, but such is life right now. If company somehow can make peace with PBMs, I will come back in.
Savient's Asset was sold in bankruptcy in Dec. of 2013 to private investors under the name of Crealta for $120 Million. That was followed by huge price increase for the drug ( the hedge fund's contribution to healthcare industry these days ), and now two years later Horizon pays $510 million for it, figuring they will increase the price of the drug. This is immoral business, I do not want to be part of it.
According to my calculations based on 402 Rx/ week of IMS reported which equates to 670 Rx when added non IMS reported sales, we are doing 7.5 to $8 Million quarterly run rate, this is in line with analysts estimates and is very nice increase from last quarter. You add the Japan royalty to that, it is even better. Of course, not every week has been this good, but it is picking up momentum. Stock price however has been going the other direction, down that is, which creates nice buying opportunity.
Morgan Stanley thinks that there are possibilities that future events may be different than their assumption, which in that case they think stock will be over $40. They have price target which is at $23 with their base case scenario. So, yes there are unknown with this puppy, but unknowns are reflected in stock price, it trades 30% bellow it's peers because of the unknowns.
They have near 1200 stores, just because the one you visited had stuff on a home department on the floor mean the entire company is run that way. I shopped at one of their stores near me, very organized, and I did not have your experience. Store was jammed with shoppers. The video on yahoo news also says they did very well. I am actually impressed with kohl's merchandising selections, and their very active, on their toes marketing efforts. One of my friend also works at one of their stores, she tells me business was very good.